136 related articles for article (PubMed ID: 28860824)
1.
Liu F; Gong M; Gao L; Cai X; Zhang H; Ma Y
Onco Targets Ther; 2017; 10():4143-4151. PubMed ID: 28860824
[TBL] [Abstract][Full Text] [Related]
2. CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.
Li M; Gao L; Li Z; Sun J; Zhang H; Duan H; Ma Y; Wang C
Oncotarget; 2016 May; 7(21):31454-65. PubMed ID: 27129146
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of secreted frizzled-related proteins predicts poor prognosis in non-M3 acute myeloid leukemia.
Guo H; Zhang TJ; Wen XM; Zhou JD; Ma JC; An C; Zhang W; Xu ZJ; Lin J; Qian J
Onco Targets Ther; 2017; 10():3635-3644. PubMed ID: 28790854
[TBL] [Abstract][Full Text] [Related]
4. [Clinical and prognostic significance of ABO promotor methylation level in adult leukemia and myelodydysplastic syndrome].
Shao M; Tang P; Lyu XP; Yang QK; Zhu WT; Jin HF; Wang L; Zhao XQ; Liu X; Sun L
Zhonghua Nei Ke Za Zhi; 2018 Nov; 57(11):816-823. PubMed ID: 30392237
[No Abstract] [Full Text] [Related]
5. CHFR hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.
Gao L; Liu F; Zhang H; Sun J; Ma Y
Genes Chromosomes Cancer; 2016 Feb; 55(2):158-68. PubMed ID: 26542416
[TBL] [Abstract][Full Text] [Related]
6. GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia.
Zhou JD; Yao DM; Zhang YY; Ma JC; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
Am J Cancer Res; 2015; 5(6):2047-55. PubMed ID: 26269763
[TBL] [Abstract][Full Text] [Related]
7. GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia.
Zhou JD; Yao DM; Zhang YY; Ma JC; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
Am J Cancer Res; 2015; 5(5):1786-94. PubMed ID: 26175946
[TBL] [Abstract][Full Text] [Related]
8. PARP-1 Overexpression as an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia.
Pashaiefar H; Yaghmaie M; Tavakkoly-Bazzaz J; Ghaffari SH; Alimoghaddam K; Momeny M; Izadi P; Izadifard M; Kasaeian A; Ghavamzadeh A
Genet Test Mol Biomarkers; 2018 Jun; 22(6):343-349. PubMed ID: 29812960
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation of the candidate tumor suppressor gene TCF21 in myelodysplastic syndrome and acute myeloid leukemia.
Gu Y; Zhou JD; Xu ZJ; Zhang TJ; Wen XM; Ma JC; Ji RB; Yuan Q; Zhang W; Chen Q; Lin J; Qian J
Am J Transl Res; 2019; 11(6):3450-3460. PubMed ID: 31312357
[TBL] [Abstract][Full Text] [Related]
11. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
12. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998
[TBL] [Abstract][Full Text] [Related]
13. Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection.
Liu ZJ; Huang Y; Wei L; He JY; Liu QY; Yu XQ; Li ZL; Zhang J; Li B; Sun CJ; Liang WB; Sun AM; Qin Y
Neoplasma; 2017; 64(5):795-802. PubMed ID: 28592132
[TBL] [Abstract][Full Text] [Related]
14. DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia.
Zhou JD; Zhang TJ; Wang YX; Yang DQ; Yang L; Ma JC; Wen XM; Yang J; Lin J; Qian J
Tumour Biol; 2016 Jul; 37(7):8951-60. PubMed ID: 26753961
[TBL] [Abstract][Full Text] [Related]
15. RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma.
Saelee P; Wongkham S; Chariyalertsak S; Petmitr S; Chuensumran U
Asian Pac J Cancer Prev; 2010; 11(6):1677-81. PubMed ID: 21338215
[TBL] [Abstract][Full Text] [Related]
16. Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia.
Lian XY; Ma JC; Zhou JD; Zhang TJ; Wu DH; Deng ZQ; Zhang ZH; Li XX; He PF; Yan Y; Lin J; Qian J
J Cell Physiol; 2019 Jun; 234(6):9438-9446. PubMed ID: 30317626
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
Wang J; Wang B; Chen X; Bi J
Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
[TBL] [Abstract][Full Text] [Related]
19. SFXN3 is Associated with Poor Clinical Outcomes and Sensitivity to the Hypomethylating Therapy in Non-M3 Acute Myeloid Leukemia Patients.
Dong Y; Jin F; Wang J; Li Q; Huang Z; Xia L; Yang M
Curr Gene Ther; 2023; 23(5):410-418. PubMed ID: 37491851
[TBL] [Abstract][Full Text] [Related]
20. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma.
Yeo W; Wong N; Wong WL; Lai PB; Zhong S; Johnson PJ
Liver Int; 2005 Apr; 25(2):266-72. PubMed ID: 15780049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
